JP2010502739A - ナトリウムチャネル阻害剤及び浸透圧調節物質を用いた処置による粘膜水和及び粘液クリアランスの改善 - Google Patents

ナトリウムチャネル阻害剤及び浸透圧調節物質を用いた処置による粘膜水和及び粘液クリアランスの改善 Download PDF

Info

Publication number
JP2010502739A
JP2010502739A JP2009527590A JP2009527590A JP2010502739A JP 2010502739 A JP2010502739 A JP 2010502739A JP 2009527590 A JP2009527590 A JP 2009527590A JP 2009527590 A JP2009527590 A JP 2009527590A JP 2010502739 A JP2010502739 A JP 2010502739A
Authority
JP
Japan
Prior art keywords
chor
group
het
conr
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009527590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502739A5 (enExample
Inventor
マイケル・アール・ジョンソン
リチャード・シー・バウチャー
アンドリュー・ジェイ・ハーシュ
Original Assignee
パリオン・サイエンシィズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パリオン・サイエンシィズ・インコーポレーテッド filed Critical パリオン・サイエンシィズ・インコーポレーテッド
Publication of JP2010502739A publication Critical patent/JP2010502739A/ja
Publication of JP2010502739A5 publication Critical patent/JP2010502739A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009527590A 2006-09-07 2007-09-07 ナトリウムチャネル阻害剤及び浸透圧調節物質を用いた処置による粘膜水和及び粘液クリアランスの改善 Pending JP2010502739A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84266906P 2006-09-07 2006-09-07
US84296306P 2006-09-08 2006-09-08
PCT/US2007/077907 WO2008031048A2 (en) 2006-09-07 2007-09-07 Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes

Publications (2)

Publication Number Publication Date
JP2010502739A true JP2010502739A (ja) 2010-01-28
JP2010502739A5 JP2010502739A5 (enExample) 2010-10-21

Family

ID=39158105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527590A Pending JP2010502739A (ja) 2006-09-07 2007-09-07 ナトリウムチャネル阻害剤及び浸透圧調節物質を用いた処置による粘膜水和及び粘液クリアランスの改善

Country Status (6)

Country Link
US (1) US7981898B2 (enExample)
EP (1) EP2059239A4 (enExample)
JP (1) JP2010502739A (enExample)
AR (1) AR062742A1 (enExample)
TW (1) TW200819430A (enExample)
WO (1) WO2008031048A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502738A (ja) * 2006-09-07 2010-01-28 パリオン・サイエンシィズ・インコーポレーテッド ナトリウムチャネル遮断剤および浸透圧調節物質での処置により粘膜水和および粘膜クリアランスを増強する方法
JP2016503027A (ja) * 2012-12-17 2016-02-01 パリオン・サイエンシィズ・インコーポレーテッド ３，５−ジアミノ−６−クロロ−ｎ−（ｎ−（４−フェニルブチル）カルバムイミドイル）ピラジン−２−カルボキサミド化合物
JP2016503028A (ja) * 2012-12-17 2016-02-01 パリオン・サイエンシィズ・インコーポレーテッド 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体
JP2016503031A (ja) * 2012-12-17 2016-02-01 パリオン・サイエンシィズ・インコーポレーテッド アリールアルキル及びアリールオキシアルキル置換の上皮ナトリウムチャネル遮断化合物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
AU2004266704B2 (en) * 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2009139948A1 (en) * 2008-02-26 2009-11-19 Johnson Michael R Poly aromatic sodium channel blockers
US20100074881A1 (en) * 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
SI2723176T1 (sl) 2011-06-27 2017-09-29 Parion Sciences, Inc. Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013181232A2 (en) 2012-05-29 2013-12-05 Michael Ross Johnson Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
SG11201601291QA (en) 2013-08-23 2016-03-30 Parion Sciences Inc Dithiol mucolytic agents
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers
BR112017016067A2 (pt) 2015-01-30 2018-04-03 Parion Sciences Inc agentes mucolíticos de monotiol
JP2018520986A (ja) 2015-04-30 2018-08-02 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解剤の新規なプロドラッグ

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501790A (ja) * 1994-02-25 1998-02-17 セントラル シドニー エリア ヘルス サービス 気道狭窄の誘起及び／または痰の誘発の方法及び装置
JP2005526726A (ja) * 2002-02-19 2005-09-08 パリオン・サイエンシィズ・インコーポレーテッド ナトリウムチャネル遮断薬
JP2010502738A (ja) * 2006-09-07 2010-01-28 パリオン・サイエンシィズ・インコーポレーテッド ナトリウムチャネル遮断剤および浸透圧調節物質での処置により粘膜水和および粘膜クリアランスを増強する方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JP3481236B2 (ja) * 1990-10-05 2003-12-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 固体粒状薬剤及び固体粒状薬剤エーロゾル投薬装置
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US6264975B1 (en) * 1998-10-20 2001-07-24 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
ATE390414T1 (de) * 1999-07-19 2008-04-15 Univ North Carolina Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
WO2001055390A1 (en) * 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
EP1670474A4 (en) * 2003-08-18 2008-08-06 Parion Sciences Inc CYCLIC PYRAZINOYLGUANIDINE AS SODIUM CHANNEL BLOCKER
AU2004266704B2 (en) * 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
CA2534568A1 (en) * 2003-08-18 2005-03-24 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) * 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7399766B2 (en) * 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) * 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501790A (ja) * 1994-02-25 1998-02-17 セントラル シドニー エリア ヘルス サービス 気道狭窄の誘起及び／または痰の誘発の方法及び装置
JP2005526726A (ja) * 2002-02-19 2005-09-08 パリオン・サイエンシィズ・インコーポレーテッド ナトリウムチャネル遮断薬
JP2010502738A (ja) * 2006-09-07 2010-01-28 パリオン・サイエンシィズ・インコーポレーテッド ナトリウムチャネル遮断剤および浸透圧調節物質での処置により粘膜水和および粘膜クリアランスを増強する方法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502738A (ja) * 2006-09-07 2010-01-28 パリオン・サイエンシィズ・インコーポレーテッド ナトリウムチャネル遮断剤および浸透圧調節物質での処置により粘膜水和および粘膜クリアランスを増強する方法
JP2016503027A (ja) * 2012-12-17 2016-02-01 パリオン・サイエンシィズ・インコーポレーテッド ３，５−ジアミノ−６−クロロ−ｎ−（ｎ−（４−フェニルブチル）カルバムイミドイル）ピラジン−２−カルボキサミド化合物
JP2016503028A (ja) * 2012-12-17 2016-02-01 パリオン・サイエンシィズ・インコーポレーテッド 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体
JP2016503031A (ja) * 2012-12-17 2016-02-01 パリオン・サイエンシィズ・インコーポレーテッド アリールアルキル及びアリールオキシアルキル置換の上皮ナトリウムチャネル遮断化合物
JP2018197263A (ja) * 2012-12-17 2018-12-13 パリオン・サイエンシィズ・インコーポレーテッド アリールアルキル及びアリールオキシアルキル置換の上皮ナトリウムチャネル遮断化合物
JP2018199697A (ja) * 2012-12-17 2018-12-20 パリオン・サイエンシィズ・インコーポレーテッド 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体
JP2019001803A (ja) * 2012-12-17 2019-01-10 パリオン・サイエンシィズ・インコーポレーテッド ３，５−ジアミノ−６−クロロ−ｎ−（ｎ−（４−フェニルブチル）カルバムイミドイル）ピラジン−２−カルボキサミド化合物

Also Published As

Publication number Publication date
WO2008031048A2 (en) 2008-03-13
US7981898B2 (en) 2011-07-19
AR062742A1 (es) 2008-12-03
WO2008031048A3 (en) 2008-07-03
EP2059239A4 (en) 2010-07-07
US20090082287A1 (en) 2009-03-26
TW200819430A (en) 2008-05-01
EP2059239A2 (en) 2009-05-20

Similar Documents

Publication Publication Date Title
US8058278B2 (en) Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
US7981898B2 (en) Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
JP4805824B2 (ja) キャップ化ピラジノイルグアニジンナトリウムチャネルブロッカー
JP5611844B2 (ja) 多環芳香族ナトリウムチャネル遮断薬
JP5225085B2 (ja) 新規なキャップ化ピラジノイルグアニジンナトリウムチャネル遮断薬
JP6010617B2 (ja) ３，５−ジアミノ−６−クロロ−ｎ−（ｎ−（４−（４−（２−（ヘキシル（２，３，４，５，６−ペンタヒドロキシヘキシル）アミノ）エトキシ）フェニル）ブチル）カルバミミドイル）ピラジン−２−カルボキサミド
JP5143557B2 (ja) 可溶性アミド及びエステルピラジノイルグアニジンナトリウムチャネル遮断薬
CA2839709C (en) A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
JP2007502829A (ja) 環状ピラジノイルグアニジンナトリウムチャネルブロッカー
JP2007502827A (ja) 脂肪族ピラジノイルグアニジンナトリウムチャネルブロッカー
KR20070026287A (ko) 병원체로부터의 감염 위험성을 감소시키는 방법
AU2004287352A1 (en) Methods of reducing risk of infection from pathogens
KR20150023302A (ko) 안구 건조 및 다른 점막 질환의 치료를 위한 나트륨 채널 차단제 활성을 보유하는 덴드리머 유사 아미노 아미드
CN101534813A (zh) 通过使用钠通道阻断剂和渗透调节剂的治疗来增加粘膜水化和粘液清除的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130319